BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33334252)

  • 1. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
    Jiang S; Mao C; Jiang B; Tan Q; Deng B
    Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCAR1 plays critical roles in the formation and immunoevasion of invasive circulating tumor cells in lung adenocarcinoma.
    Mao CG; Jiang SS; Wang XY; Tao SL; Jiang B; Mao CY; Yang YL; Hu ZY; Long T; Jin H; Tan QY; Huang Y; Deng B
    Int J Biol Sci; 2021; 17(10):2461-2475. PubMed ID: 34326687
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients.
    Deng B; Sun Z; Jason W; Yang P
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S701-8. PubMed ID: 23904007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.
    Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P
    Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
    Liu DG; Xue L; Li J; Yang Q; Peng JZ
    Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
    Liu T; Li Y; Song J; Li B; Wang R; Huang T; Qin Y
    Cancer Control; 2024; 31():10732748241251562. PubMed ID: 38716503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protumor Effects of Histone H3-H4 Chaperone Antisilencing Feature 1B Gene on Lung Adenocarcinoma: In Silico and
    Wu L; Jie B
    Comput Math Methods Med; 2021; 2021():5005459. PubMed ID: 34956399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
    Li TT; Liu H; Li FP; Hu YF; Mou TY; Lin T; Yu J; Zheng L; Li GX
    World J Gastroenterol; 2015 Dec; 21(47):13259-67. PubMed ID: 26715808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance.
    Zhou J; Zhu X; Wu S; Guo J; Zhang K; Xu C; Chen H; Jin Y; Sun Y; Zheng S; Chen Y
    Cancer Biol Med; 2020 Feb; 17(1):169-180. PubMed ID: 32296584
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer.
    Chen J; Ye C; Dong J; Cao S; Hu Y; Situ B; Xi X; Qin S; Xu J; Cai Z; Zheng L; Wang Q
    J Transl Med; 2020 Feb; 18(1):59. PubMed ID: 32028979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.
    Pore M; Meijer C; de Bock GH; Boersma-van Ek W; Terstappen LW; Groen HJ; Timens W; Kruyt FA; Hiltermann TJ
    Clin Lung Cancer; 2016 Nov; 17(6):535-542. PubMed ID: 27363902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
    Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
    Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.